These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 193079)

  • 1. The tumor enhancing property of herpes simplex virus type-2 (HSV-2).
    Reiss-Gutfreund RJ; Dostal V; Binder M; Letnansky K
    Osterr Z Onkol; 1977; 3(5-6):148-54. PubMed ID: 193079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced lysis of herpes simplex virus type 1-infected mouse cell lines by NC and NK effectors.
    Colmenares C; Lopez C
    J Immunol; 1986 May; 136(9):3473-80. PubMed ID: 2420891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.
    Chahlavi A; Rabkin S; Todo T; Sundaresan P; Martuza R
    Gene Ther; 1999 Oct; 6(10):1751-8. PubMed ID: 10516725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the relationship of the immunological status of Herpes simplex virus type-2 (HSV-2) infected animals and the tumor-enhancing property of this infection.
    Reiss-Gutfreund RJ; Dostal V; Fanta D
    Osterr Z Onkol; 1977 Oct; 4(2-3):35-9. PubMed ID: 201898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the immuno-suppressive activity of Herpes simplex virus type 2 and the tumor enhancing potential of the virus on Yoshida sarcoma.
    Reiss-Gutfreund RJ; Dostal V
    Osterr Z Onkol; 1975; 2(2-3):63-8. PubMed ID: 174048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity.
    Kohl S; Loo LS
    J Immunol; 1982 Jul; 129(1):370-6. PubMed ID: 6282968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
    Toda M; Martuza RL; Kojima H; Rabkin SD
    J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tumours in mice chronically infected with herpes simplex virus.
    Barinsky IF; Spynu KI; Talalaeva AF; Vanag KA
    Acta Virol; 1979 Sep; 23(5):367-74. PubMed ID: 42295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
    Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
    Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
    Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus.
    Tolo FM; Rukunga GM; Muli FW; Njagi EN; Njue W; Kumon K; Mungai GM; Muthaura CN; Muli JM; Keter LK; Oishi E; Kofi-Tsekpo MW
    J Ethnopharmacol; 2006 Mar; 104(1-2):92-9. PubMed ID: 16198524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of herpes simplex virus-specific helper T lymphocyte precursors in the lymph node cells of infected mice.
    Prymowicz D; Moore RN; Rouse BT
    J Immunol; 1985 Apr; 134(4):2683-8. PubMed ID: 2579150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of herpes simplex virus infection to target cells on recognition of minor histocompatibility antigens by cytotoxic T lymphocytes.
    Kuzushima K; Isobe K; Morishima T; Takatsuki A; Nakashima I
    J Immunol; 1990 Jun; 144(12):4536-40. PubMed ID: 2161874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
    Yasukawa M; Zarling JM
    J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.